(Q39487974)

12 September 2017

title

Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study (English)

1 reference

12 September 2017

1 reference

Benjamin L Maughan

1

1 reference

12 September 2017

Brandon Luber

series ordinal

2

1 reference

12 September 2017

Rosa Nadal

series ordinal

3

1 reference

12 September 2017

Emmanuel S Antonarakis

series ordinal

4

1 reference

12 September 2017

publication date

16 August 2016

1 reference

12 September 2017

1 reference

12 September 2017

volume

77

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

33-40

1 reference

Abiraterone and increased survival in metastatic prostate cancer

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Androgen pathway resistance in prostate cancer and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Sequencing of agents in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23246

21 January 2018

Identifiers

DOI

10.1002/PROS.23246

1 reference

release_uoaj7e5opne6ze3md5bxqt5f7u

12 September 2017

Fatcat ID

0 references

1 reference